Composition

"active ingredient: febuxostat;

1 film-coated tablet contains febuxostat 80 mg or 120 mg;

excipients: microcrystalline cellulose; lactose, monohydrate; croscarmellose sodium; hydroxypropyl cellulose; sodium lauryl sulfate; lactose anhydrous; colloidal silicon dioxide anhydrous; magnesium stearate;

film coating: polyvinyl alcohol (E 1203), titanium dioxide (E 171), polyethylene glycol (macrogol 3350) (E 1521), talc (E 553b), iron oxide yellow (E 172)."

Indications

"EUROFEB in 80 mg and 120 mg doses:

Treatment of chronic hyperuricaemia in diseases accompanied by urate crystal deposition, including current or previous history of tophi and/or gouty arthritis.

EUROFEB in a dose of 120 mg:

Treatment and prevention of hyperuricaemia in adult patients undergoing chemotherapy for haematological malignancies with moderate to high risk of tumour lysis syndrome (TLS).

Contraindications

Hypersensitivity to the active substance or to any other excipient of the drug specified in the "Composition" section.

Routes of Administration and Dosage Take orally.

"For oral administration.

EUROFEB is administered orally, regardless of food intake.

Children.

The safety and efficacy of febuxostat in children under 18 years of age have not been established. There are no data on their use."

This information about medicinal products, including prescription drugs, is intended for information purposes only and is not a guide for self-diagnosis and/or treatment.
The use of medicinal products is possible only as prescribed by a physician and after prior consultation with him/her. Self-medication can be harmful to your health.